CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results and business highlights for the third quarter ended September 30, 2015. Management will host a conference call today at 8:30 a.m. ET to provide a business update and review the Company’s third quarter financial results.
Help employers find you! Check out all the jobs and post your resume.
